Rare and Orphan Diseases - Global Oncology Academy

Episodes 1-16 of 43

Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
Project Oncology®
Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
- Marlene Mimi Maeusli, PhD.
Refining Multimodal Therapy for Mesothelioma: Clinical Impact of SMART Sequencing
Refining Multimodal Therapy for Mesothelioma: Clinical Impact of SMART Sequencing
Project Oncology®
Refining Multimodal Therapy for Mesothelioma: Clinical Impact of SMART Sequencing
- John Cho, MD, PhD, FRCPC
CAR T in Marginal Zone Lymphoma: Insights from the TRANSCEND FL Study
CAR T in Marginal Zone Lymphoma: Insights from the TRANSCEND FL Study
Project Oncology®
CAR T in Marginal Zone Lymphoma: Insights from the TRANSCEND FL Study
- Charles Turck, PharmD, BCPS, BCCCP
- Sairah Ahmed, MD
The SMART Protocol in Mesothelioma: Challenges and Opportunities for Global Adoption
The SMART Protocol in Mesothelioma: Challenges and Opportunities for Global Adoption
Project Oncology®
The SMART Protocol in Mesothelioma: Challenges and Opportunities for Global Adoption
- John Cho, MD, PhD, FRCPC
Ibrutinib-Venetoclax in Relapsed CLL: MRD-Guided Approach Balances Efficacy and Safety
Ibrutinib-Venetoclax in Relapsed CLL: MRD-Guided Approach Balances Efficacy and Safety
Project Oncology®
Ibrutinib-Venetoclax in Relapsed CLL: MRD-Guided Approach Balances Efficacy and Safety
Prognostic Value of Red Cell Distribution Width at Ruxolitinib Initiation in Myelofibrosis
Prognostic Value of Red Cell Distribution Width at Ruxolitinib Initiation in Myelofibrosis
Project Oncology®
Prognostic Value of Red Cell Distribution Width at Ruxolitinib Initiation in Myelofibrosis
Immunotherapy Advances in Squamous Cell Anal Carcinoma: A New Standard of Care
Immunotherapy Advances in Squamous Cell Anal Carcinoma: A New Standard of Care
Project Oncology®
Immunotherapy Advances in Squamous Cell Anal Carcinoma: A New Standard of Care
- Charles Turck, PharmD, BCPS, BCCCP
- Marwan G. Fakih, MD
Large Cell Neuroendocrine Carcinoma Care: A Look at Evolving Approaches
Large Cell Neuroendocrine Carcinoma Care: A Look at Evolving Approaches
Project Oncology®
Large Cell Neuroendocrine Carcinoma Care: A Look at Evolving Approaches
- Balazs Halmos, MD, MS
Differentiating Large Cell Neuroendocrine Carcinoma from Other Lung Cancers
Differentiating Large Cell Neuroendocrine Carcinoma from Other Lung Cancers
Project Oncology®
Differentiating Large Cell Neuroendocrine Carcinoma from Other Lung Cancers
- Balazs Halmos, MD, MS
From Infusion Chair to Clinic Visit: How Subcutaneous Nivolumab May Simplify RCC Care
From Infusion Chair to Clinic Visit: How Subcutaneous Nivolumab May Simplify RCC Care
Project Oncology®
From Infusion Chair to Clinic Visit: How Subcutaneous Nivolumab May Simplify RCC Care
SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
Project Oncology®
SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
Personalizing Care for Large Cell Neuroendocrine Carcinoma
Personalizing Care for Large Cell Neuroendocrine Carcinoma
Project Oncology®
Personalizing Care for Large Cell Neuroendocrine Carcinoma
- Junaid Arshad, MD, MS
Treating Gastrointestinal Neuroendocrine Carcinoma: Beyond Lung-Based Approaches
Treating Gastrointestinal Neuroendocrine Carcinoma: Beyond Lung-Based Approaches
Project Oncology®
Treating Gastrointestinal Neuroendocrine Carcinoma: Beyond Lung-Based Approaches
- Namrata Vijayvergia, MD
Diagnosing LCNEC of the Lung: Challenges and Strategies
Diagnosing LCNEC of the Lung: Challenges and Strategies
Project Oncology®
Diagnosing LCNEC of the Lung: Challenges and Strategies
- Junaid Arshad, MD, MS
The Evolving Treatment Landscape for Extrapulmonary Neuroendocrine Carcinomas
The Evolving Treatment Landscape for Extrapulmonary Neuroendocrine Carcinomas
Project Oncology®
The Evolving Treatment Landscape for Extrapulmonary Neuroendocrine Carcinomas
- Namrata Vijayvergia, MD
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Project Oncology®
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target

Prev
1
2
3
Next

1/3